Extract of Prunus persica flesh (PPFE) improves chemotherapeutic efficacy and protects against nephrotoxicity in cisplatin-treated mice.
Cisplatin (cis-diamminedichloroplatinum II) is one of the most effective chemotherapeutic agents used in the treatment of a variety of human solid tumors. However, its clinical use is rather limited as a result of severe nephrotoxicity. The principal objective of this study was to evaluate the protective effect of Prunus persica flesh extract (PPFE) against cisplatin-induced nephrotoxicity in animal models, and whether its use influences the therapeutic efficacy of cisplatin. The administration of PPFE alone significantly inhibited the growth of CT-26 colon carcinoma xenografted onto mice without adverse effects. The combination of PPFE and cisplatin enhanced the inhibitory effect of cisplatin against tumor growth. In a xenograft model involving the repeated administration of low-dose cisplatin for 15 days, and in an acute toxicity model involving a single administration of high-dose cisplatin over a 16 h period, the administration of PPFE in combination with and prior to the cisplatin injection reversed the cisplatin-induced reduction in the kidney weight. PPFE blocked the increases in the serum blood urea nitrogen and creatinine levels associated with the kidney damage. Moreover, the administration of PPFE induced a significant reduction in cisplatin-induced oxidative stress. These results indicate that PPFE may promote the therapeutic efficacy of cisplatin therapy, while attenuating its inherent nephrotoxicity.
Lee
Chang Ki
CK
Department of Oral Biology, Oral Cancer Research Institute, Oral Science Research Institute and Brain Korea 21 Project, Yonsei University College of Dentistry, Seoul, Korea.
Park
Kwang-Kyun
KK
Hwang
Jae-Kwan
JK
Lee
Sang Kook
SK
Chung
Won-Yoon
WY
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001806:Blood Urea Nitrogen; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000009:adverse effects*; D003110:Colonic Neoplasms / Q000473:pathology; D003404:Creatinine / Q000097:blood; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D015227:Lipid Peroxidation; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008813:Mice, Inbred ICR; D009569:Nitric Oxide / Q000097:blood; D010936:Plant Extracts / Q000494:pharmacology*; D027861:Prunus / Q000737:chemistry; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D010936:Plant Extracts; D009569:Nitric Oxide; D003404:Creatinine; D002945:Cisplatin